Welcome to our dedicated page for Amesite SEC filings (Ticker: AMST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amesite Inc. filings document an emerging growth, smaller reporting company whose common stock trades on Nasdaq under AMST. Recent Form 8-K disclosures cover material agreements, Regulation FD shareholder updates, Nasdaq continued-listing matters, changes in the company’s independent registered public accounting firm, and updates on the NurseMagic AI-native documentation and workflow platform for non-acute care.
The company’s registration and financing filings describe securities offerings, shelf registration use, common stock, pre-funded warrants, private-placement warrants, resale registration matters, and related stockholder-approval mechanics. These filings also provide formal disclosure on capital structure, governance, risk factors, and public-company reporting obligations.
Amesite Inc. entered into an At The Market Offering Agreement on July 17, 2026 with H.C. Wainwright & Co., LLC as sales agent, allowing Amesite to offer and sell shares of its common stock from time to time, up to a maximum aggregate offering price defined as the “Maximum Amount” in the agreement. Sales will be made as at-the-market offerings on The Nasdaq Capital Market or by other permitted methods at market prices or as otherwise agreed with the agent, under an effective Form S-3 shelf registration statement and related prospectus supplement.
H.C. Wainwright will use commercially reasonable efforts to execute sales based on Amesite’s instructions, and Amesite is not obligated to sell any shares, nor is the agent obligated to purchase shares on a principal basis. Amesite will pay a 3.0% commission on aggregate gross proceeds from each sale and reimburse specified expenses, including up to $50,000 of the agent’s legal fees and costs. Net proceeds, if any, are intended for general corporate and working capital purposes, with management retaining broad discretion over their allocation. The at-the-market program will end when all shares covered by the agreement are sold or the agreement is terminated under its terms.
Amesite Inc., an AI-focused healthcare technology company, established an at-the-market equity program with H.C. Wainwright & Co. to sell up to $2,266,112 of common stock from time to time. Shares may be sold on Nasdaq under the symbol AMST, with Wainwright acting as sales agent and earning a 3.0% commission on gross proceeds.
As of March 31, 2026, common shares outstanding were 4,748,001, and assuming sales of 1,970,532 shares at an illustrative price of $1.15, shares outstanding would rise to 8,520,383. At that assumed level, as adjusted net tangible book value would increase to $0.34 per share, implying immediate dilution of $0.81 per share to new investors. Amesite plans to use any net proceeds for general corporate and working capital purposes while warning that investing in its stock involves a high degree of risk and that it does not anticipate paying cash dividends.
Amesite Inc. reported results of its July 13, 2026 annual meeting of stockholders. Stockholders of record on May 22, 2026, when 5,852,985 shares of common stock were outstanding, were entitled to vote. A total of 2,321,797 shares, or approximately 40% of outstanding shares, were represented, constituting a quorum under the company’s bylaws. Stockholders elected Ann Marie Sastry, Ph.D. and Barbie Brewer as Class II directors for three-year terms and ratified Novogradac & Company LLP as independent registered public accounting firm for the year ending June 30, 2026.
Stockholders also approved amending the 2018 Equity Incentive Plan to increase the number of shares available for issuance under the plan by 1,000,000 shares and separately increase the number of shares that may be issued pursuant to the exercise of incentive stock options by 1,000,000 shares. In addition, in accordance with Nasdaq Listing Rule 5635(d), stockholders approved the issuance of an aggregate of 1,393,732 shares of common stock upon exercise of the company’s Series A-1 warrants and an aggregate of 1,393,732 shares of common stock upon exercise of its Series A-2 warrants.
Amesite Inc. reported that Chief Financial Officer Sarah Berman received a grant of stock options as part of her compensation. The award covers 10,000 options to purchase common stock at an exercise price of $1.1400 per share, expiring on June 29, 2036. According to the vesting terms, 25% of the options vest on June 29, 2027, and the remaining options vest in equal monthly installments over the following 36 months. After this grant, she holds 10,000 stock options directly.
Amesite Inc. chief financial officer Sarah Berman reported a compensation-related stock option grant. She received options to buy 2,500 shares of common stock at an exercise price of $3.05 per share, expiring on May 22, 2035. According to the vesting terms under the 2018 Equity Incentive Plan, 25% of the shares vest on May 22, 2026, with the remaining shares vesting in equal monthly installments over 36 months.
Parmer George reported acquisition or exercise transactions in this Form 4 filing.
Amesite Inc. director George Parmer received a grant of 9,023 restricted stock units as compensation. These RSUs were issued as deferred stock units in lieu of cash fees earned for serving as a director, with the number based on the closing share price on the last day of the quarter.
Each unit represents a right to receive one share of Amesite common stock or the cash equivalent. The deferred stock units or cash equivalent will be delivered after Parmer completes service on the board or upon an earlier change in control. Following this award, his directly held equity position reported in this filing totals 76,910 shares or share-equivalent units.
OMENN GILBERT S reported acquisition or exercise transactions in this Form 4 filing.
Amesite Inc. director Gilbert S. Omenn, through the Gilbert S. Omenn Revocable Trust, received a grant of 9,023 restricted stock units as compensation for board service. Each RSU represents a contingent right to one share of common stock or its cash equivalent, to be delivered after board service ends or upon a change in control. Following this award, indirect holdings reported for this trust total 83,806 shares underlying RSUs.
LOSH J MICHAEL reported acquisition or exercise transactions in this Form 4 filing.
Amesite Inc. director J. Michael Losh, through the J. Michael Losh Irrevocable Qualified Annuity Trust #7, received a grant of 10,902 restricted stock units as deferred stock units in lieu of cash director fees. Each unit represents one share of AMST common stock or its cash equivalent, deliverable after board service ends or upon an earlier change in control. Following this award, the trust holds 101,265 units in total.
Brewer Barbie reported acquisition or exercise transactions in this Form 4 filing.
Amesite Inc. director Barbie Brewer received a grant of 10,432 restricted stock units as board compensation. Each RSU represents a right to receive one share of common stock or its cash equivalent. The units were issued in lieu of cash fees and will be settled when board service ends or upon a change in control.
Amesite Inc. is calling a virtual annual stockholder meeting on July 13, 2026 to vote on key governance and financing items. Stockholders of record as of May 22, 2026, when 5,852,985 common shares were outstanding, may participate and vote online.
Proposals include re-electing two directors, ratifying Novogradac & Company LLP as the new independent auditor, amending the 2018 Equity Incentive Plan to add 1,000,000 shares for future awards, and approving the issuance of up to 2,787,464 shares upon exercise of private placement warrants. The proxy explains quorum, broker non-votes, director independence, board committees and director compensation, highlighting Amesite’s reliance on stock-based incentives to attract and retain executives, employees and non-employee directors.